Research and Markets - Global Cystic Fibrosis Therapeutics Market 2016-2020 With AbbVie, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals Dominating

DUBLIN, November 7, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Cystic Fibrosis Therapeutics Market 2016-2020" report to their offering.

The global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.

Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction.

The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

According to the report, improvement in diagnostic technologies is a key driver aiding to the growth of this market. There has been an increase in research activities involved in the development of various diagnostic tools for cystic fibrosis. For instance, scientists at Stanford University have developed a DNA test for the accurate and comprehensive screening of newborns for cystic fibrosis. This test utilizes the next-generation DNA sequencing which can identify the entire CFTR gene rather than just looking at selected mutations. This is considered to be less expensive and less time-consuming technology, which will contribute to this market's growth in the coming years.

Key vendors

• AbbVie
• F. Hoffmann-La Roche
• Gilead Sciences
• Novartis
• Vertex Pharmaceuticals

Other prominent vendors

• Advanced Inhalation Therapies (AIT)
• Alaxia SAS
• Alcresta Therapeutics
• AlgiPharma
• Allergan
• Anthera
• AstraZeneca
• Bayer
• Celtaxsys
• Chiesi Farmaceutici
• Corbus Pharmaceuticals
• Cyclacel Pharmaceuticals
• Digestive Care
• Galapagos
• Grifols
• Insmed Incorporated
• Kamada
• Nivalis Therapeutics
• Novoteris
• Parion Sciences
• Pharmaxis
• ProQR Therapeutics
• Protalix Biotherapeutics
• Proteostasis Therapeutics
• PTC Therapeutics
• Pulmatrix
• Savara
• SolAeroMed
• Vectura

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation by drug class

Part 09: Market segmentation by molecule type

Part 10: Geographical segmentation

Part 11: Key leading countries

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Co-pay and assistance programs by vendors

Part 17: Vendor landscape

Part 18: Key vendor analysis

Part 19: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/5lsnh7/global_cystic

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call [phone]

For U.S./CAN Toll Free Call [phone]

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]